Enhertu achieved a median progression-free survival of 13.2 months versus 8.1 months for chemotherapy, with a higher objective response rate of 62.6% compared to 34.4%. This summary was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback